Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 31 March 2009, doi:10.1136/bmj.b1303
Cite this as: BMJ 2009;338:b1303
| The first 150 words of the full text of this article appear below. |
Type I allergy carries the risk of incorrect self treatment.1 In patients with type I allergy and established systemic reactions, treatment includes self injection of adrenaline with prefilled devices—the EpiPen device is constructed to look like a ballpoint pen. Unfortunately it is constructed as an upside-down pen: the needle emerges from what at first glance seems to be the button end of the pen, not the end where one would expect the ink covered ballpoint tip to emerge.
Consequently, during the 2008 wasp season, we experienced two cases of adverse self injection in the thumb. Sixty seven patients with wasp stings were seen, 16 of whom presented with systemic allergic reactions. Six of the 16 were already known to have such reactions and had attempted auto-injection of adrenaline. In two of the six patients, the procedure was wrongly performed: one auto-injected into the thumb, and another never received adrenaline because
Per Lav Madsen1, Nick Mattsson2
1 Department of Cardiology, Rigshospitalet 2142, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark, 2 Department of Internal Medicine, Nykøbing Falster Community Hospital, Denmark
per.lav.madsen@rh.dk